Serum Essential Elements and Survival after Cancer Diagnosis
- PMID: 37299574
- PMCID: PMC10255054
- DOI: 10.3390/nu15112611
Serum Essential Elements and Survival after Cancer Diagnosis
Abstract
In a prospective study, we measured the associations between three serum elements (Se, Zn and Cu) and the prognosis of 1475 patients with four different types of cancer (breast, prostate, lung and larynx) from University Hospitals in Szczecin, Poland. The elements were measured in serum taken after diagnosis and prior to treatment. Patients were followed from the date of diagnosis until death from any cause or until the last follow-up date (mean years of follow-up: 6.0-9.8 years, according to site). Kaplan-Meier curves were constructed for all cancers combined and for each cancer separately. Age-adjusted hazard ratios (HRs) were estimated using Cox regression. The outcome was all-cause mortality. A Se level in the highest quartile was also associated with a reduced mortality (HR = 0.66; 95%CI 0.49-0.88; p = 0.005) in all-cause mortality for all cancers combined. Zn level in the highest quartile was also associated with reduced mortality (HR = 0.55; 95%CI 0.41-0.75; p = 0.0001). In contrast, a Cu level in the highest quartile was associated with an increase in mortality (HR = 1.91; 95%CI 1.56-2.08; p = 0.0001). Three serum elements-selenium, zinc and copper-are associated with the prognosis of different types of cancer.
Keywords: breast cancer; copper; laryngeal cancer; lung cancer; prostate cancer; selenium; survival; zinc.
Conflict of interest statement
Jan Lubiński is the CEO of Read-Gene SA, which offers measurements on a micro-and macroelement level. These authors are part-time employees of Read-Gene: W.M., R.D., C.C., J.G. and T.H. The other authors declare that they have no conflicts of interest.
Figures




Similar articles
-
The association between essential trace element (copper, zinc, selenium, and cobalt) status and the risk of early embryonic arrest among women undergoing assisted reproductive techniques.Front Endocrinol (Lausanne). 2022 Oct 26;13:906849. doi: 10.3389/fendo.2022.906849. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387879 Free PMC article.
-
Selenium, Copper, Zinc Concentrations and Cu/Zn, Cu/Se Molar Ratios in the Serum of Patients with Acute Ischemic Stroke in Northeastern Poland-A New Insight into Stroke Pathophysiology.Nutrients. 2021 Jun 22;13(7):2139. doi: 10.3390/nu13072139. Nutrients. 2021. PMID: 34206577 Free PMC article.
-
Within- and between-subject biological variation data for serum zinc, copper and selenium obtained from 68 apparently healthy Turkish subjects.Clin Chem Lab Med. 2021 Oct 22;60(4):533-542. doi: 10.1515/cclm-2021-0886. Print 2022 Mar 28. Clin Chem Lab Med. 2021. PMID: 34700367
-
Status and potential diagnostic roles of essential trace elements in Kashin- Beck disease patients.J Trace Elem Med Biol. 2022 Jan;69:126880. doi: 10.1016/j.jtemb.2021.126880. Epub 2021 Oct 25. J Trace Elem Med Biol. 2022. PMID: 34717166 Review.
-
Esophagus cancer and essential trace elements.Front Public Health. 2022 Nov 16;10:1038153. doi: 10.3389/fpubh.2022.1038153. eCollection 2022. Front Public Health. 2022. PMID: 36466456 Free PMC article. Review.
Cited by
-
Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients.Nutrients. 2024 Feb 14;16(4):527. doi: 10.3390/nu16040527. Nutrients. 2024. PMID: 38398851 Free PMC article.
-
Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy.Cancers (Basel). 2024 Feb 2;16(3):647. doi: 10.3390/cancers16030647. Cancers (Basel). 2024. PMID: 38339398 Free PMC article. Review.
-
Blood and Serum Copper and Zinc Levels and 10-Year Survival of Patients After Kidney Cancer Diagnosis.Nutrients. 2025 Mar 8;17(6):944. doi: 10.3390/nu17060944. Nutrients. 2025. PMID: 40289930 Free PMC article.
-
Evaluation of Mortality Risk Factors in Prostate Cancer: Impact of Demographic, Clinical, Laboratory, Therapeutic, and Trace Element Influences.Cancer Rep (Hoboken). 2025 Mar;8(3):e70166. doi: 10.1002/cnr2.70166. Cancer Rep (Hoboken). 2025. PMID: 40067073 Free PMC article.
-
Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy.Discov Oncol. 2025 May 16;16(1):783. doi: 10.1007/s12672-025-02601-4. Discov Oncol. 2025. PMID: 40377782 Free PMC article.
References
-
- de Jong V.M., Wang Y., ter Hoeve N.D., Opdam M., Stathonikos N., Jóźwiak K., Hauptmann M., Cornelissen S., Vreuls W., Rosenberg E.H., et al. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J. Clin. Oncol. 2022;40:2361–2374. doi: 10.1200/JCO.21.01536. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical